top of page
  • Completed
    • Dec 22, 2018

NCT03489525: Phase 1: MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma (MEDI2228)

Updated: May 26, 2022

NCT03489525: Phase 1: MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma (MEDI2228)


MEDI2228

The purpose of this study is to assess the safety, pharmacokinetics and tolerability, describe the dose-limiting toxicities (DLTs), and determine the maximum tolerated dose (MTD) or maximum administered dose (MAD [in the absence of establishing the MTD]) for single agent MEDI2228 in adult subjects with multiple myeloma who are either transplant ineligible or post autologous stem cell transplant and are relapsed/refractory


Sponsor

MedImmune LLC


Multiple Locations

International Study

 

Official Title: A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma

First Posted: April 5, 2018


https://clinicaltrials.gov/ct2/show/NCT03489525

 

Biological: Dose Escalation, MEDI2228, ADC (antibody drug conjugate